<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00033592</url>
  </required_header>
  <id_info>
    <org_study_id>NCCTG-N99C4</org_study_id>
    <secondary_id>CDR0000069303</secondary_id>
    <secondary_id>NCI-P02-0220</secondary_id>
    <nct_id>NCT00033592</nct_id>
  </id_info>
  <brief_title>Comparison of Nicotine Inhaler and/or Bupropion in Helping People to Stop Smoking and Prevent the Recurrence of Smoking</brief_title>
  <official_title>Phase III Trial Comparing Nicotine Inhaler Versus Bupropion Versus Nicotine Inhaler Plus Bupropion For Smoking Cessation Efficacy And Relapse Prevention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alliance for Clinical Trials in Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Alliance for Clinical Trials in Oncology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Use of a nicotine inhaler and/or bupropion may be effective in helping people stop
      smoking and prevent them from starting smoking again. It is not yet known whether a nicotine
      inhaler or bupropion are more effective alone or combined for stopping smoking.

      PURPOSE: Randomized phase III trial to compare the effectiveness of the nicotine inhaler or
      bupropion alone to that of the nicotine inhaler combined with bupropion in helping people to
      stop smoking and prevent starting smoking again.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Compare the effectiveness of nicotine inhaler vs bupropion vs nicotine inhaler
      plus bupropion on smoking cessation and prevention of relapse in participants who currently
      smoke. II. Compare the reduction in the rate of relapse to smoking after initial abstinence
      in participants treated long term with these regimens.

      OUTLINE: This is a randomized, double-blind, placebo-controlled, multicenter study. Patients
      are stratified according to gender, cigarettes smoked per day at time of screening (10-39 vs
      40 or more), and total length of smoking in years (less than 5 vs 5-9 vs 10 or more).
      Participants are randomized to one of three treatment arms. Arm I: Participants receive 6-16
      nicotine inhaler cartridges per day. Arm II: Participants receive oral bupropion 1-2 times
      daily. Arm III: Participants receive 6-16 nicotine inhaler cartridges per day and oral
      bupropion 1-2 times daily. In all arms, treatment continues for 12 weeks. After 12 weeks,
      participants are randomized a second time based on whether they continue to smoke or are
      smoke-free. Participants randomized to arm I who continue to smoke are randomized to one of
      two treatment arms. Arm IV: Participants receive oral bupropion 1-2 times daily for 12 weeks
      Arm V: Participants receive oral placebo 1-2 times daily for 12 weeks. Participants
      randomized to arm II who continue to smoke are randomized to one of two treatment arms. Arm
      VI: Participants receive 6-16 nicotine inhaler cartridges per day for 12 weeks. Arm VII:
      Participants receive 6-16 placebo inhaler cartridges per day for 12 weeks. Participants
      randomized to arm III who continue to smoke do not receive any further therapy. Participants
      randomized to arm I who are smoke-free are randomized to one of two treatment arms. Arm VIII:
      Participants receive 6-16 nicotine inhaler cartridges per day for 40 weeks. Arm IX:
      Participants receive 6-16 placebo inhaler cartridges per day for 40 weeks. Participants
      randomized to arm II who are smoke-free are randomized to one of two treatment arms. Arm X:
      Participants receive oral bupropion 1-2 times daily for 40 weeks. Arm XI: Participants
      receive oral placebo 1-2 times daily for 40 weeks. Participants randomized to arm III who are
      smoke-free are randomized to one of four treatment arms. Arm XII: Participants receive 6-16
      nicotine inhaler cartridges per day and oral placebo 1-2 times daily for 40 weeks. Arm XIII:
      Participants receive 6-16 placebo inhaler cartridges per day and oral bupropion 1-2 times
      daily for 40 weeks. Arm XIV: Participants receive 6-16 nicotine inhaler cartridges per day
      and oral bupropion 1-2 times daily for 40 weeks. Arm XV: Participants receive 6-16 placebo
      inhaler cartridges per day and oral placebo 1-2 times daily for 40 weeks. All participants
      are followed every month for 6 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2002</start_date>
  <completion_date type="Actual">July 2006</completion_date>
  <primary_completion_date type="Actual">July 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prevention in relapse</measure>
    <time_frame>Up to 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction in the rate of relapse</measure>
    <time_frame>Up to 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>15</number_of_arms>
  <enrollment type="Actual">1708</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I: nicotine inhaler cartridges</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive 6-16 nicotine inhaler cartridges per day. Treatment continues for 12 weeks. After 12 weeks, participants are randomized a second time based on whether they continue to smoke or are smoke-free.
Participants randomized to arm I who continue to smoke are randomized to one of two treatment arms Arm IV or Arm V. Participants randomized to arm I who are smoke-free are randomized to one of two treatment arms Arm VIII or Arm IX.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II: bupropion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive oral bupropion 1-2 times daily.
Treatment continues for 12 weeks. After 12 weeks, participants are randomized a second time based on whether they continue to smoke or are smoke-free. After 12 weeks, participants are randomized a second time based on whether they continue to smoke or are smoke-free.
Participants randomized to arm II who continue to smoke are randomized to one of two treatment arms Arm VI or Arm VII. Participants randomized to arm II who are smoke-free are randomized to one of two treatment arms Arm Arm X or Arm XI.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm III: nicotine inhaler cartridges</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive 6-16 nicotine inhaler cartridges per day and oral bupropion 1-2 times daily. Treatment continues for 12 weeks. After 12 weeks, participants are randomized a second time based on whether they continue to smoke or are smoke-free.
Participants randomized to arm III who continue to smoke do not receive any further therapy. Participants randomized to arm III who are smoke-free are randomized to one of four treatment arms Arm XII, Arm XIII, Arm XIV or Arm XV.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm IV: bupropion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive oral bupropion 1-2 times daily for 12 weeks.
All participants are followed every month for 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm V: placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants receive oral placebo 1-2 times daily for 12 weeks.
All participants are followed every month for 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm VI: nicotine inhaler cartridges</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive 6-16 nicotine inhaler cartridges per day for 12 weeks.
All participants are followed every month for 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm VII: placebo inhaler</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants receive 6-16 placebo inhaler cartridges per day for 12 weeks.
All participants are followed every month for 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm VIII: nicotine inhaler cartridges</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive 6-16 nicotine inhaler cartridges per day for 40 weeks.
All participants are followed every month for 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm IX: placebo inhaler cartridges</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants receive 6-16 placebo inhaler cartridges per day for 40 weeks.
All participants are followed every month for 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm X: bupropion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive oral bupropion 1-2 times daily for 40 weeks.
All participants are followed every month for 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm XI: placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants receive oral placebo 1-2 times daily for 40 weeks.
All participants are followed every month for 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm XII: nicotine inhaler cartridges</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive 6-16 nicotine inhaler cartridges per day and oral placebo 1-2 times daily for 40 weeks.
All participants are followed every month for 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm XIII: placebo inhaler cartridges</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants receive 6-16 placebo inhaler cartridges per day and oral bupropion 1-2 times daily for 40 weeks.
All participants are followed every month for 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm XIV: nicotine inhaler cartridges</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive 6-16 nicotine inhaler cartridges per day and oral bupropion 1-2 times daily for 40 weeks.
All participants are followed every month for 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm XV: placebo inhaler cartridges</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants receive 6-16 placebo inhaler cartridges per day and oral placebo 1-2 times daily for 40 weeks.
All participants are followed every month for 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>Arm V: placebo</arm_group_label>
    <arm_group_label>Arm VII: placebo inhaler</arm_group_label>
    <arm_group_label>Arm IX: placebo inhaler cartridges</arm_group_label>
    <arm_group_label>Arm XI: placebo</arm_group_label>
    <arm_group_label>Arm XIII: placebo inhaler cartridges</arm_group_label>
    <arm_group_label>Arm XV: placebo inhaler cartridges</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bupropion hydrochloride</intervention_name>
    <arm_group_label>Arm II: bupropion</arm_group_label>
    <arm_group_label>Arm IV: bupropion</arm_group_label>
    <arm_group_label>Arm X: bupropion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nicotine</intervention_name>
    <arm_group_label>Arm I: nicotine inhaler cartridges</arm_group_label>
    <arm_group_label>Arm III: nicotine inhaler cartridges</arm_group_label>
    <arm_group_label>Arm VI: nicotine inhaler cartridges</arm_group_label>
    <arm_group_label>Arm VIII: nicotine inhaler cartridges</arm_group_label>
    <arm_group_label>Arm XII: nicotine inhaler cartridges</arm_group_label>
    <arm_group_label>Arm XIV: nicotine inhaler cartridges</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Currently smoking at least 10 cigarettes per day Smoked regularly
        for the past year Motivated to use study medication More than 30 days since prior use of
        tobacco products other than cigarettes (e.g., smokeless tobacco, pipes, cigars, or snuff)
        No active chemical dependence of drug other than nicotine (e.g., alcohol, marijuana,
        cocaine, heroin, or other illicit drugs) within the past year

        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Not specified Life
        expectancy: Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not
        specified Cardiovascular: No unstable angina, myocardial infarction, or cardiac arrhythmias
        within the past 3 months Other: Not pregnant or nursing Negative pregnancy test Fertile
        patients must use effective contraception for at least 3 months prior to and during study
        Good health by medical history No history of seizure disorder No epilepsy No prior serious
        head trauma or other predisposing factors to seizures (e.g., alcohol withdrawal, febrile
        seizures during childhood, brain tumor, cerebrovascular accident, or family history of
        idiopathic seizure disorder) No known hypersensitivity or allergy to nicotine, menthol, or
        bupropion No prior or concurrent diagnosis of bulimia or anorexia nervosa No other member
        of household currently enrolled on this study No bipolar disorder, psychosis, or
        schizophrenia

        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: Not specified
        Endocrine therapy: More than 30 days since prior systemic steroids Radiotherapy: Not
        specified Surgery: Not specified Other: More than 30 days since other prior behavioral or
        pharmacologic smoking- cessation program (e.g., behavioral therapy, nicotine replacement
        therapy, clonidine, bupropion, nortriptyline, or doxepin) More than 30 days since prior
        investigational drugs More than 30 days since prior antipsychotics or antidepressants More
        than 30 days since prior theophylline More than 30 days since prior monoamine oxidase
        inhibitor More than 30 days since prior medication containing bupropion No concurrent
        antiepileptic medications No concurrent medications known to lower seizure threshold No
        other concurrent investigational drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard D. Hurt, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CCOP - Scottsdale Oncology Program</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259-5404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MBCCOP-Howard University Cancer Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Illinois Oncology Research Association</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Carle Cancer Center</name>
      <address>
        <city>Urbana</city>
        <state>Illinois</state>
        <zip>61801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Cedar Rapids Oncology Project</name>
      <address>
        <city>Cedar Rapids</city>
        <state>Iowa</state>
        <zip>52403-1206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Iowa Oncology Research Association</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50309-1016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siouxland Hematology-Oncology</name>
      <address>
        <city>Sioux City</city>
        <state>Iowa</state>
        <zip>51101-1733</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Wichita</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214-3882</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Kansas - Wichita</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Ochsner</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Ann Arbor Regional</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Duluth</name>
      <address>
        <city>Duluth</city>
        <state>Minnesota</state>
        <zip>55805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Cancer Center</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CentraCare Clinic</name>
      <address>
        <city>Saint Cloud</city>
        <state>Minnesota</state>
        <zip>56303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Metro-Minnesota</name>
      <address>
        <city>Saint Louis Park</city>
        <state>Minnesota</state>
        <zip>55416</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Missouri Valley Cancer Consortium</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medcenter One Health System</name>
      <address>
        <city>Bismarck</city>
        <state>North Dakota</state>
        <zip>58501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Merit Care Hospital</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altru Health Systems</name>
      <address>
        <city>Grand Forks</city>
        <state>North Dakota</state>
        <zip>58201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Toledo Community Hospital Oncology Program</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43623-3456</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Sooner State</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Geisinger Clinic and Medical Center</name>
      <address>
        <city>Danville</city>
        <state>Pennsylvania</state>
        <zip>17822-2001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rapid City Regional Hospital</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57709</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Sioux Community Cancer Consortium</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allan Blair Cancer Centre</name>
      <address>
        <city>Regina</city>
        <state>Saskatchewan</state>
        <zip>S4T 7T1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 9, 2002</study_first_submitted>
  <study_first_submitted_qc>February 5, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2004</study_first_posted>
  <last_update_submitted>July 12, 2016</last_update_submitted>
  <last_update_submitted_qc>July 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>non-small cell lung cancer</keyword>
  <keyword>small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
    <mesh_term>Bupropion</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

